Science Catching Up to What the Body Already Knew
OATD-01 is a first-in-class chitotriosidase inhibitor entering Phase 2 trials for pulmonary sarcoidosis. It modulates macrophage-driven inflammation and fibrosis. Researchers identified Th17.1 cells as the primary source of IFN-γ in pulmonary sarcoidosis, not classical Th1. The finding is linked to disease chronicity and glucocorticoid resistance. Methotrexate is emerging as an alternative first-line treatment to prednisone. Fewer side effects. Slower onset. I have pulmonary fibrosis. Bronchiectasis. COPD. The most likely cause is sarcoidosis, but getting that diagnosed requires doctors who actually do the doctor stuff. For 12 years I've been in and out of pulmonologists. For the first 4 years I couldn't inhale or exhale enough, without coughing until I either threw up or started spewing blood, to do the breath tests they kept ordering. Not the point though. The point is: the research is finally shifting. The mechanistic understanding is changing. The treatment path...